Literature DB >> 6301696

Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells.

M G Masucci, M T Bejarano, G Masucci, E Klein.   

Abstract

The effect of lymphocyte subsets, separated on the basis of cell density, on Epstein-Barr virus (EBV)-induced B-cell proliferation was studied. The experiments were performed with lymphocytes of seropositive individuals. After 2 weeks of culture, the growth of B cells was inhibited by the T subset, which is also active in natural killer assays, i.e., the low-buoyant density lymphocyte fractions. However, if the cultures were observed for a longer time, the initial growth regressed even in cultures containing the subsets which did not have natural killing (NK) function, i.e., those with high cell density. The initial cell concentration at which the cultures were seeded determined the outcome of the experiments and the demonstration of inhibitory effects. An important difference was seen between the subsets with regard to radiosensitivity. The prompt inhibitory effect of the NK-positive subset remained after irradiation, while the function of the NK-negative one was abrogated. In the presence of the irradiated T-enriched total population, infected B cells (BEBV) grew. Consequently, the radiation-resistant effector compartment, represented by the low-density cells, was not sufficient to counteract the establishment of BEBV lines. They contributed, nevertheless, to the regression because the kinetics of B-cell growth were different in cultures containing separated high-density cells or the total population. In the former, growth continued for a longer time and complete regression occurred only in the cultures initiated with high cell concentrations. The experiments showed that two types of cells contribute to the regression of BEBV growth in cultures initiated with lymphocytes of seropositive donors. One acts promptly and is independent of cell proliferation; another is activated for proliferation by encounter with B blasts.

Entities:  

Mesh:

Year:  1983        PMID: 6301696     DOI: 10.1016/0008-8749(83)90374-x

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  19 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells.

Authors:  J I Cohen; K Lekstrom
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 4.  Evolving principles in immunopathology: interleukin 10 and its relationship to Epstein-Barr virus protein BCRF1.

Authors:  K W Moore; F Rousset; J Banchereau
Journal:  Springer Semin Immunopathol       Date:  1991

5.  Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.

Authors:  J Tanner; G Tosato
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

6.  Immunologic abnormalities in chronic fatigue syndrome.

Authors:  N G Klimas; F R Salvato; R Morgan; M A Fletcher
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

7.  The effect of leucyl-leucine methyl ester on proliferation and Ig secretion of EBV-transformed human B lymphocytes.

Authors:  M Ohlin; L Danielsson; R Carlsson; C A Borrebaeck
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

8.  Suppressive role of NK cells in pokeweed mitogen-induced immunoglobulin synthesis: effect of depletion/enrichment of Leu 11b+ cells.

Authors:  P D Mason; A P Weetman; J G Sissons; L K Borysiewicz
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

9.  Immune function in chronic active Epstein-Barr virus infection.

Authors:  R Kibler; D O Lucas; M J Hicks; B T Poulos; J F Jones
Journal:  J Clin Immunol       Date:  1985-01       Impact factor: 8.317

10.  Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis.

Authors:  G Tosato; A D Steinberg; R Yarchoan; C A Heilman; S E Pike; V De Seau; R M Blaese
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.